The cell cycle inhibitors p21(WAF1) and p27(KIP1) are associated with survival in patients treated by salvage prostatectomy after radiation therapy

Clinical Cancer Research

Volumn 6, Issue 5, 2000, Pages 1896-1899

  Cheng, Liang ^a   Lloyd, Ricardo V ^b   Weaver, Amy L ^b   Pisansky, Thomas M ^b   Cheville, John C ^b   Ramnani, Dharamdas M ^b   Leibovich, Bradley C ^b   Blute, Michael L ^b   Zincke, Horst ^b   Bostwich, David G ^b,c  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MAYO CLINIC   (United States)

^c BOSTWICK LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMITOTIC AGENT; PROTEIN P21; PROTEIN P27;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; GENE EXPRESSION; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; PELVIS LYMPHADENECTOMY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RECURRENT CANCER;

AGED; CELL CYCLE PROTEINS; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLIN-DEPENDENT KINASE INHIBITOR P27; CYCLINS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICROTUBULE-ASSOCIATED PROTEINS; MIDDLE AGED; NEOPLASM STAGING; PROPORTIONAL HAZARDS MODELS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; SALVAGE THERAPY; SURVIVAL ANALYSIS; TUMOR SUPPRESSOR PROTEINS;

EID: 0034109296     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Kuban, D. A., and Schellhammer, P. F. Prognostic significance of post-irradiation prostate biopsies. Oncology, 7: 29-38, 1993.
2. Cheng, L., Sebo, T. J., Slezak, J., Pisansky, T. M., Bergstralh, E. J., Neumann, R. M., Iczkowski, K. A., Zincke, H., and Bostwick, D. G. Predictors of survival in prostate cancer patients treated with salvage radical prostatectomy after radiation therapy. Cancer (Phila.), 83: 2164-2171, 1998.
3. Lerner, S. E., Blute, M. L., and Zincke, H. Critical evaluation of salvage surgery for radio-recurrent/resistant prostate cancer. J. Urol., 154: 1103-1109, 1995.
4. Sherr, C. J. Cancer cell cycles. Science (Washington DC), 174: 1672-1677, 1996.
5. Cordon-Cardo, C. Mutations of cell cycle regulators. Biological and clinical implications for human neoplasia. Am. J. Pathol., 147: 545-560, 1995.
6. Hartwell, L. H., and Kastan, M. B. Cell cycle control and cancer. Science (Washington DC), 266: 1821-1828, 1994.
7. Cheville, J. C., Lloyd, R. V., Sebo, T. J., Cheng, L., Erickson, L., Bostwick, D. G., Lohse, C. M., and Wollan, P. Expression of p27kip1 in prostatic adenocarcinoma. Mod. Pathol., 11: 324-328, 1998.
8. Kip1 gene expression in benign prostatic hyperplasia and prostatic carcinoma. J. Natl. Cancer Inst., 90: 1284-1291, 1998.
9. Yang, R. M., Naitoh, J., Murphy, M., Wang, H., Phillipson, J., DeKernion, J. B., Loda, M., and Reiter, R. E. Low p27 expression predicts poor disease-free survival in patients with prostate cancer. J. Urol., 159: 941-945, 1998.
10. ip1 is a novel prognostic factor in localized human prostate adenocarcinoma. Cancer Res., 58: 542-548, 1997.
11. Kip1 and Ki-67 in benign and malignant thyroid tumors. Mod. Pathol., 11: 169-174, 1998.
12. Kip1 protein: prognostic implications in primary breast cancer. Nat. Med., 2: 227-230, 1997.
13. Loda, M., Cukor, B., Tam, S. W., Lavin, P., Fiorentino, M., Draetta, G. F., Jessup, J. M., and Pagano, M. Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nat. Med., 3: 231-234, 1997.
14. Kip1 expression in endocrine and other tumors. Am. J. Pathol., 750: 401-405, 1997.
15. Waldman, R., Zhang, Y., Dillehay, L., Yu, J., Kinzler, K., Vogelstein, B., and Williams, J. Cell-cycle arrest versus cell death in cancer therapy. Nat. Med., 3: 1034-1036, 1997.
16. Wang, Y. A., Elson, A., and Leder, P. Loss of p21 increases sensitivity to ionizing radiation and delays the onset of lymphoma in atm-deficient mice. Proc. Natl. Acad. Sci. USA, 94: 14590-14595, 1997.
17. Waf1/Cip1 sensitizes to radiation by an apoptosis-independent mechanism. Cancer Res., 57: 4703-4706, 1997.
18. Brugarlos, J., Chandrasekaran, C., Gordon, J. I., Beach, D., Jacks, T., and Hannon, G. J. Radiation-induced cell cycle arrest compromised by p21 deficiency. Nature (Lond.), 377: 552-557, 1995.
19. Matsushima, H., Sasaki, T., Goto, T., Hosaka, Y., Homma, Y., Kitamura, T., Kawabe, K., Sakamoto, A., Murakami, T., and Machinami, R. Immunohistochemical study of p21WAF1 and p53 proteins in prostatic cancer and their prognostic significance. Hum. Pathol., 29: 778-783, 1998.
20. Ljung, G., Egevad, L., Norberg, M., Holmberg, L., Nilsson, S., and Busch, C. Expression of p21 and mutant p53 gene products in residual prostatic tumor cells after radical radiotherapy. Prostate, 32: 99-105, 1997.
21. Altman, D. G., Lausen, B., Sauerbrei, W., and Schumacher, M. Dangers of using "optimal" cutpoints in the evaluation of prognostic factors. J. Natl. Cancer Inst., 86: 829-835, 1994.
22. Cheng, L., Sebo, T. J., Cheville, J. C., Slezak, J., Bergstralh, E. J., Paceli, A., Neumann, R. M., Zincke, H., and Bostwick, D. G. p53 protein overexpression is associated with increased cell proliferation in patients with locally recurrent prostate carcinoma after radiation therapy. Cancer (Phila.), 85: 1293-1299, 1999.